CRNX
Price
$29.96
Change
-$0.45 (-1.48%)
Updated
Jun 27 closing price
Capitalization
2.81B
40 days until earnings call
DNTH
Price
$17.63
Change
-$0.50 (-2.76%)
Updated
Jun 27 closing price
Capitalization
566.66M
Interact to see
Advertisement

CRNX vs DNTH

Header iconCRNX vs DNTH Comparison
Open Charts CRNX vs DNTHBanner chart's image
Crinetics Pharmaceuticals
Price$29.96
Change-$0.45 (-1.48%)
Volume$1.64M
Capitalization2.81B
Dianthus Therapeutics
Price$17.63
Change-$0.50 (-2.76%)
Volume$789.41K
Capitalization566.66M
CRNX vs DNTH Comparison Chart in %
Loading...
CRNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DNTH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRNX vs. DNTH commentary
Jun 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRNX is a Buy and DNTH is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 29, 2025
Stock price -- (CRNX: $29.96 vs. DNTH: $17.63)
Brand notoriety: CRNX and DNTH are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRNX: 213% vs. DNTH: 294%
Market capitalization -- CRNX: $2.81B vs. DNTH: $566.66M
CRNX [@Biotechnology] is valued at $2.81B. DNTH’s [@Biotechnology] market capitalization is $566.66M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRNX’s FA Score shows that 0 FA rating(s) are green whileDNTH’s FA Score has 0 green FA rating(s).

  • CRNX’s FA Score: 0 green, 5 red.
  • DNTH’s FA Score: 0 green, 5 red.
According to our system of comparison, DNTH is a better buy in the long-term than CRNX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRNX’s TA Score shows that 2 TA indicator(s) are bullish while DNTH’s TA Score has 2 bullish TA indicator(s).

  • CRNX’s TA Score: 2 bullish, 6 bearish.
  • DNTH’s TA Score: 2 bullish, 5 bearish.
According to our system of comparison, DNTH is a better buy in the short-term than CRNX.

Price Growth

CRNX (@Biotechnology) experienced а -1.77% price change this week, while DNTH (@Biotechnology) price change was +4.60% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +31.22%, and the average quarterly price growth was +12.91%.

Reported Earning Dates

CRNX is expected to report earnings on Aug 08, 2025.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRNX($2.81B) has a higher market cap than DNTH($567M). DNTH YTD gains are higher at: -19.128 vs. CRNX (-41.404). DNTH has higher annual earnings (EBITDA): -116.76M vs. CRNX (-373.49M). CRNX has more cash in the bank: 1.27B vs. DNTH (263M). DNTH has less debt than CRNX: DNTH (1.4M) vs CRNX (50.8M). DNTH has higher revenues than CRNX: DNTH (6.52M) vs CRNX (760K).
CRNXDNTHCRNX / DNTH
Capitalization2.81B567M496%
EBITDA-373.49M-116.76M320%
Gain YTD-41.404-19.128216%
P/E RatioN/A3.24-
Revenue760K6.52M12%
Total Cash1.27B263M484%
Total Debt50.8M1.4M3,639%
FUNDAMENTALS RATINGS
CRNX vs DNTH: Fundamental Ratings
CRNX
DNTH
OUTLOOK RATING
1..100
6111
VALUATION
overvalued / fair valued / undervalued
1..100
92
Overvalued
50
Fair valued
PROFIT vs RISK RATING
1..100
6763
SMR RATING
1..100
9495
PRICE GROWTH RATING
1..100
6480
P/E GROWTH RATING
1..100
10067
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

DNTH's Valuation (50) in the null industry is somewhat better than the same rating for CRNX (92) in the Pharmaceuticals Major industry. This means that DNTH’s stock grew somewhat faster than CRNX’s over the last 12 months.

DNTH's Profit vs Risk Rating (63) in the null industry is in the same range as CRNX (67) in the Pharmaceuticals Major industry. This means that DNTH’s stock grew similarly to CRNX’s over the last 12 months.

CRNX's SMR Rating (94) in the Pharmaceuticals Major industry is in the same range as DNTH (95) in the null industry. This means that CRNX’s stock grew similarly to DNTH’s over the last 12 months.

CRNX's Price Growth Rating (64) in the Pharmaceuticals Major industry is in the same range as DNTH (80) in the null industry. This means that CRNX’s stock grew similarly to DNTH’s over the last 12 months.

DNTH's P/E Growth Rating (67) in the null industry is somewhat better than the same rating for CRNX (100) in the Pharmaceuticals Major industry. This means that DNTH’s stock grew somewhat faster than CRNX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRNXDNTH
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 3 days ago
84%
Momentum
ODDS (%)
Bearish Trend 3 days ago
81%
Bearish Trend 3 days ago
84%
MACD
ODDS (%)
Bearish Trend 3 days ago
85%
Bullish Trend 3 days ago
85%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
78%
Bullish Trend 3 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
79%
Bearish Trend 3 days ago
90%
Advances
ODDS (%)
N/A
N/A
Declines
ODDS (%)
Bearish Trend 3 days ago
79%
Bearish Trend 3 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 10 days ago
86%
Bearish Trend 3 days ago
83%
Aroon
ODDS (%)
Bearish Trend 3 days ago
86%
Bearish Trend 3 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
CRNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DNTH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JAMRX91.680.74
+0.81%
Janus Henderson Research T
MWOCX49.240.33
+0.67%
MFS Global Growth C
PADEX22.060.10
+0.46%
Putnam Dynamic Asset Allocation Gr R5
BMIDX17.810.08
+0.45%
Brown Advisory Mid-Cap Growth Investor
BRSYX14.290.06
+0.42%
MFS Blended Research Small Cap Eq R6

CRNX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRNX has been loosely correlated with XNCR. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if CRNX jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRNX
1D Price
Change %
CRNX100%
-0.10%
XNCR - CRNX
58%
Loosely correlated
-3.10%
TRDA - CRNX
57%
Loosely correlated
-1.57%
DYN - CRNX
56%
Loosely correlated
-4.78%
IDYA - CRNX
55%
Loosely correlated
-4.13%
RVMD - CRNX
55%
Loosely correlated
-1.52%
More

DNTH and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNTH has been loosely correlated with IMNM. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if DNTH jumps, then IMNM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNTH
1D Price
Change %
DNTH100%
-2.76%
IMNM - DNTH
51%
Loosely correlated
-0.23%
ERAS - DNTH
50%
Loosely correlated
N/A
CRNX - DNTH
48%
Loosely correlated
-0.10%
XNCR - DNTH
48%
Loosely correlated
-3.10%
SYRE - DNTH
47%
Loosely correlated
-4.99%
More